AstraZeneca’s experimental breast cancer pill, camizestrant, is facing a prolonged review period in the United States after the Food and Drug Administration requested supplementary data. The Anglo-Swedish pharmaceutical giant confirmed that the FDA has extended its assessment timeline to examine additional information submitted by the company.
FDA Extension and Advisory Panel Vote
This development follows an April vote by a majority of the FDA’s advisory panel against the drug when used in combination with a CDK4/6 inhibitor. The panel’s reservations were centred on the design of a crucial late-stage trial, rather than any concerns over safety or efficacy. In response, AstraZeneca has submitted further analyses requested by the regulator to strengthen its new drug application. These include data on longer-term efficacy outcomes, which are scheduled to be presented at a conference on June 2.
Company Response
Susan Galbraith, a senior executive at AstraZeneca, stated: “We look forward to continuing the dialogue with the FDA in order to bring the benefits of camizestrant with this innovative treatment strategy to eligible patients in the US as quickly as possible.”
Drug Specifics and European Progress
Camizestrant is specifically developed for patients battling a form of breast cancer characterised by tumours carrying a particular mutation. The news of the FDA delay comes shortly after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of the drug last week. This discrepancy highlights the differing regulatory approaches on either side of the Atlantic.
